Chadbourne has a long history of serving and representing companies in the pharmaceutical industry through a full range of legal practices, including products liability and commercial litigation, corporate transactions, intellectual property and tax matters. Lawyers throughout the firm effectively serve the needs of our pharmaceutical clients, which include manufacturers and distributors of both over-the-counter and prescription products as well as other medical devices.
Chadbourne litigators have advised pharmaceutical companies in all facets of litigation in federal and state courts across the country. From serving as national counsel in connection with products liability litigation to import pricing and FDA-approval efforts, our litigators have extensive experience handling a wide variety of matters. Complex litigation for pharmaceutical companies often involves not just a single proceeding, but numerous related simultaneously. The firm has strong capabilities in managing complex, multi-jurisdictional litigation across the country as national or coordinating counsel—skills critical to formulating and maintaining consistent strategy and legal and factual themes.
Chadbourne has also advised public and private pharmaceutical companies on all aspects of corporate transactions and tax matters. Our clients also include financial institutions, venture capital firms and other investors who provide financing to such companies. Experience with a range of clients gives us the skills to address legal matters arising at companies of any size, from mature multinationals to start-ups developing their first products.
Donald Strauber has 50 years of experience in complex commercial litigation and heads up matters in courts throughout the United States. He has worked primarily in three areas: health-related litigation, federal securities litigation and shareholder derivative suits. He is in charge of Jim Beam’...
Mary T. Yelenick focuses her practice on complex products liability litigation; client risk-management; and compliance issues.